📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

Corvus Pharmaceuticals Inc (CRVS)

NASDAQ
Currency in USD
Disclaimer
5.560
-0.080(-1.42%)
Closed
Pre Market
5.770+0.210(+3.78%)
CRVS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
5.4105.689
52 wk Range
1.0506.150
Prev. Close
5.56
Open
5.64
Day's Range
5.41-5.689
52 wk Range
1.05-6.15
Volume
217,724
Average Volume (3m)
364,479
1-Year Change
273.15%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
CRVS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
10.125
Upside
+82.104%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Corvus Pharmaceuticals Inc Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Compare CRVS to Peers and Sector

Metrics to compare
CRVS
Peers
Sector
Relationship
P/E Ratio
−15.4x−3.0x−0.6x
PEG Ratio
−0.320.000.00
Price/Book
6.8x2.4x2.6x
Price / LTM Sales
-35.7x3.2x
Upside (Analyst Target)
43.9%211.4%46.5%
Fair Value Upside
Unlock18.9%6.6%Unlock

People Also Watch

11.700
RAIL
-6.63%
3.6500
RMTI
+0.27%
42.28
AMRK
-3.95%
32.20
CDNA
+4.17%
218.11
PI
-0.11%

FAQ

What Is the Corvus Pharmaceuticals (CRVS) Stock Price Today?

The Corvus Pharmaceuticals stock price today is 5.56

What Stock Exchange Does Corvus Pharmaceuticals Trade On?

Corvus Pharmaceuticals is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Corvus Pharmaceuticals?

The stock symbol for Corvus Pharmaceuticals is "CRVS."

What Is the Corvus Pharmaceuticals Market Cap?

As of today, Corvus Pharmaceuticals market cap is 347.79M.

What is Corvus Pharmaceuticals Earnings Per Share?

The Corvus Pharmaceuticals EPS is -0.437.

What Is the Next Corvus Pharmaceuticals Earnings Date?

Corvus Pharmaceuticals will release its next earnings report on Oct 31, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.